Pfizer finalizes $2.2B acquisition of Trillium
Pfizer Inc. said on Wednesday it has completed the acquisition of Trillium Therapeutics Inc. in a deal worth $2.2 billion, or $18.5 per share.
The deal between the two pharmaceutical companies was initially announced on August 23.
“Today’s announcement combines Pfizer’s research and global development capabilities with Trillium’s innovative discoveries, allowing us to accelerate breakthroughs that change [oncology] patients’ lives,” Pfizer Chief Development Officer Chris Boshoff commented.
Get involved!
Comments